Rintatolimod (Ampligen)

polyinosinic:polycytidylic acid-poly-L-lysine-carboxymethylcellulose complex (poly-ICLC) · Hemispherx Biopharma

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Rintatolimod (Ampligen), covering 2025-06-24 to 2025-06-24. Get the full timeline:

Most recent: Clinical Trial Update: Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer [Phase 1, Phase 2]

See pricing